Dec 3, 2025 | Press Releases
New CPT I Code, OPPS and MPFS Decisions Recognize Significant Clinical Value Across Care Settings BOSTON – December 3, 2025 – Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for...
Jul 7, 2025 | Press Releases
Cardiac CT Expert to Advance Research and Commercialization of Company’s PlaqueIQTM Image Analysis Software BOSTON – July 7, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive...
Mar 3, 2025 | Press Releases
BOSTON – March 3, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added several senior members to its clinical and commercial teams. The...
Oct 1, 2024 | In the News
First and Only Software Validated on Ground-Truth Histology, the Gold Standard for Plaque Characterization BOSTON, Oct. 1, 2024 – Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis...
Jul 22, 2024 | In the News
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software BOSTON, July 22, 2024 – Elucid, a pioneering AI medical technology company providing physicians with imaging...
